Review
Open access
Jul 2026
Lipoprotein(a) and Cardiovascular Risk: Emerging Therapeutic Perspectives with Implications for Chronic Kidney Disease
Chronic kidney disease (CKD) represents a clinically relevant setting in which Lp(a) levels may rise as renal function declines, contributing to the excess cardiovascular burden and residual risk left unaddressed by historical statin trials in the end-stage renal disease population.
L. Di Lullo, Paola Peverini, Antonio Bellasi et al.
· CardioRenal Medicine · 0 citations